X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare with ASTRAZENECA PHARMA - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs ASTRAZENECA PHARMA - Comparison Results

ASTRAZENECA PHARMA 
   Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES ASTRAZENECA PHARMA ALKEM LABORATORIES/
ASTRAZENECA PHARMA
 
P/E (TTM) x - 117.8 - View Chart
P/BV x 7.6 16.8 45.4% View Chart
Dividend Yield % 0.6 0.0 -  

Financials

 ALKEM LABORATORIES   ASTRAZENECA PHARMA
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-16
ASTRAZENECA PHARMA
Mar-14
ALKEM LABORATORIES/
ASTRAZENECA PHARMA
5-Yr Chart
Click to enlarge
High Rs1,5891,285 123.7%   
Low Rs1,232634 194.3%   
Sales per share (Unadj.) Rs417.5189.6 220.2%  
Earnings per share (Unadj.) Rs56.3-0.2 -27,649.8%  
Cash flow per share (Unadj.) Rs64.73.8 1,683.1%  
Dividends per share (Unadj.) Rs12.700-  
Dividend yield (eoy) %0.90-  
Book value per share (Unadj.) Rs292.968.6 426.8%  
Shares outstanding (eoy) m119.5725.00 478.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.45.1 66.8%   
Avg P/E ratio x25.1-4,712.7 -0.5%  
P/CF ratio (eoy) x21.8249.6 8.7%  
Price / Book Value ratio x4.814.0 34.4%  
Dividend payout %22.60-   
Avg Mkt Cap Rs m168,65323,988 703.1%   
No. of employees `000NA1.6 0.0%   
Total wages/salary Rs m9,1711,605 571.6%   
Avg. sales/employee Rs ThNM3,040.2-  
Avg. wages/employee Rs ThNM1,029.2-  
Avg. net profit/employee Rs ThNM-3.3-  
INCOME DATA
Net Sales Rs m49,9154,740 1,053.1%  
Other income Rs m1,64592 1,786.2%   
Total revenues Rs m51,5614,832 1,067.1%   
Gross profit Rs m8,482-130 -6,534.9%  
Depreciation Rs m1,006101 993.9%   
Interest Rs m6710-   
Profit before tax Rs m8,451-139 -6,084.2%   
Minority Interest Rs m-1140-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0139 0.0%   
Tax Rs m1,6065 31,552.1%   
Profit after tax Rs m6,731-5 -132,243.6%  
Gross profit margin %17.0-2.7 -620.5%  
Effective tax rate %19.0-3.7 -518.6%   
Net profit margin %13.5-0.1 -12,557.2%  
BALANCE SHEET DATA
Current assets Rs m27,0622,726 992.6%   
Current liabilities Rs m15,3242,435 629.3%   
Net working cap to sales %23.56.1 382.5%  
Current ratio x1.81.1 157.7%  
Inventory Days Days6774 90.2%  
Debtors Days Days4141 101.3%  
Net fixed assets Rs m12,6101,035 1,218.0%   
Share capital Rs m23950 478.2%   
"Free" reserves Rs m34,490942 3,659.8%   
Net worth Rs m35,0271,716 2,041.2%   
Long term debt Rs m1,2120-   
Total assets Rs m54,3874,156 1,308.6%  
Interest coverage x13.6NM-  
Debt to equity ratio x00-  
Sales to assets ratio x0.91.1 80.5%   
Return on assets %13.6-0.1 -11,112.3%  
Return on equity %19.2-0.3 -6,478.8%  
Return on capital %24.90-  
Exports to sales %12.95.7 227.1%   
Imports to sales %3.16.5 47.8%   
Exports (fob) Rs m6,461270 2,391.2%   
Imports (cif) Rs m1,540306 502.9%   
Fx inflow Rs m6,563375 1,752.1%   
Fx outflow Rs m3,012470 640.6%   
Net fx Rs m3,552-96 -3,717.0%   
CASH FLOW
From Operations Rs m7,259-8 -89,611.1%  
From Investments Rs m1,864-146 -1,279.5%  
From Financial Activity Rs m-9,273862 -1,075.5%  
Net Cashflow Rs m-150709 -21.2%  

Share Holding

Indian Promoters % 66.9 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 33.1 0.3 11,033.3%  
FIIs % 0.0 15.7 -  
ADR/GDR % 0.0 0.0 -  
Free float % 0.0 9.1 -  
Shareholders   68,381 12,856 531.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   JUBILANT LIFE SCIENCES  PANACEA BIOTECH  CADILA HEALTHCARE  NOVARTIS  PLETHICO PHARMA  

Compare ALKEM LABORATORIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Surges 300 Points; Tata Steel Up 3.5%(01:30 pm)

After opening the day in green, share markets in India have continued the momentum and are presently trading near all-time high levels. Sectoral indices are trading on a positive note.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Mutual Funds Clearly Tell Us That There is a Bubble in the Stock Market(Vivek Kaul's Diary)

Jan 11, 2018

The maximum amount of money ever has come into equity mutual funds during the current financial year.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Jan 23, 2018 03:30 PM

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES 8-QTR ANALYSIS

COMPARE ALKEM LABORATORIES WITH

MARKET STATS